Torrent Pharmaceuticals Limited has completed the electronic dispatch of its postal ballot notice to shareholders seeking approval for the appointment of Shanti Ekambaram as an Independent Director. The company confirmed on August 6, 2026, that the notice was sent via email to members registered as of the July 31, 2026 cut-off date, in compliance with Ministry of Corporate Affairs (MCA) circulars and SEBI Listing Regulations. This procedural step activates the voting window for the special resolution, which aims to bring Ms. Ekambaram’s extensive financial services expertise to the Board to strengthen governance frameworks.

The voting process is governed by Section 110 of the Companies Act, 2013, Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In adherence to MCA General Circulars No. 14/2020, 17/2020, and 03/2025, physical copies of the ballot were not distributed; instead, Central Depository Services (India) Limited (CDSL) facilitates e-voting. The Company Secretary, Chintan M. Trivedi, signed the intimation filed with stock exchanges on August 6, confirming the dispatch was completed on August 5, 2026.

Ms. Ekambaram, aged 63, brings 39 years of experience in financial services, including a 35-year tenure at Kotak Mahindra Bank where she served as Deputy Managing Director until 2025. She previously led Kotak Mahindra Capital Company and holds directorships at Havells India Limited, Kotak Securities Limited, and Kotak Mahindra Capital Company Limited. Her appointment is proposed for a term of three consecutive years, effective from July 30, 2026, subject to shareholder assent. She is not liable to retire by rotation under Section 149(13) read with the explanation to Section 152(6) of the Companies Act, 2013.

Key Voting Details

Members holding shares in physical or demat form as of the cut-off date are eligible to vote. Individual demat holders can access the e-voting facility via their depository login credentials on the CDSL platform. Non-individual members and those holding physical shares must register on the CDSL e-voting portal using their folio or beneficiary details. Technical support for CDSL and NSDL logins is available through dedicated helpdesk channels provided in the notice.

Board Composition and Remuneration

Upon confirmation by shareholders, Ms. Ekambaram will serve as a member of the Audit Committee, Securities Transfer and Stakeholders Relationship Committee, and the Nomination and Remuneration Committee. She does not hold any shares in Torrent Pharmaceuticals Limited and has no relationship with other directors or key managerial personnel. Since her interim appointment as an Additional Director on July 30, 2026, she has attended one board meeting and received remuneration of ₹ 1 lakh in the form of sitting fees. Her future remuneration will be determined in accordance with Resolution No. 9 of the 51st Annual General Meeting Notice dated May 24, 2024, or subsequent resolutions passed by members. Rajesh Parekh & Co. has been appointed as the scrutinizer, with Aishwarya Parekh of RPAP & Co. serving as the alternate scrutinizer to ensure the fairness and transparency of the voting process.

A notable block trade in torrent pharmaceuticals was recorded on the National Stock Exchange (NSE), drawing attention from market participants. The transaction involved approximately 59,070 shares, executed at a price of ₹4961.50 per share, aggregating to a total deal value of ₹29.31 crores.

Block Trade Details

The following table summarizes the key parameters of the block trade:

Market Significance

Block trades are large, privately negotiated transactions that are executed on the exchange platform and are typically associated with institutional investors such as mutual funds, foreign portfolio investors, or other large entities. Such trades are closely monitored by market participants as they can reflect significant shifts in institutional positioning within a stock. The block trade in Torrent Pharmaceuticals at ₹4961.50 per share, covering approximately 59,070 shares, represents a transaction of considerable size on the NSE.